Skip to content

Released Nov 1, 2018, after the close

10-Q filed Nov 1, 2018, 32 days after period end · 0001564590-18-026214

Q3 2018 · 10-Q
Revenue$1.03M±0.0% vs Q3 2017−0.1% vs Q2 2018
Net Income-$16.78MN/M vs Q3 2017N/M vs Q2 2018
EPS Diluted-$0.31N/M vs Q3 2017N/M vs Q2 2018
Operating Income-$16,692,000N/M
Operating Cash Flowderived-$3,556,000N/M
Free Cash Flowderived-$4,280,000N/M
Margins · derived
Operating margin-1626.9%−619.1 pt vs Q3 2017
Net margin-1635.7%−594.3 pt vs Q3 2017

What the release said

The release

Same quarter

MetricQ3 2018Q3 2017Q3 2016Q3 2015
Revenue$1.03M$1.03M$1.03M$1.03M
Net Income-$16.78M-$10.68M-$8.74M-$6.89M
EPS Diluted-$0.31-$0.26-$0.27-$0.24

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Fate Therapeutics Inc · CIK 1434316 · Engraved from SEC EDGAR